Operation Warp Speed
| Operation Warp Speed |
(Structural deep event, Big Pharma)
|Membership||• Moncef Slaoui|
• Gustave F. Perna
• Peter Marks
• Janet Woodcock
• Bruce Tromberg
• Lee Payne
• Sean Biggerstaff
• Matt Hepburn
• Stacy Cummings
• Andrew Kilianski
|extremely sinister vaccine project|
Operation Warp Speed is a U.S. public-private national program to facilitate, at an unprecedented pace and expense, the development, manufacturing, and distribution of a COVID-19 vaccine to the entire US population by January 2021.
Operation Warp Speed is reportedly the brainchild of Presidential Adviser and son-in-law Jared Kushner. It is being formally run by the Health and Human Services Secretary Alex Azar and Defense Secretary Mark Esper who will work with a new Vaccine Czar. The Vaccine Czar selected for Kushner’s Operation Warp Speed is former GlaxoSmithKline Chairman of its Vaccines Division, Morrocan-born US citizen, Dr. Moncef Slaoui.
Normally a vaccine takes 10 years to develop, due to safety tests, but in this case, Big Pharma companies have been fully indemnified by the US government against liabilities should vaccine recipients die or develop serious disease as a result of the hyper-rushed vaccine.
Fourteen promising candidates have been chosen from the 100+ vaccine candidates currently in development for Covid-19 — some of them already in clinical trials with U.S. government support, which will be reduced to 3-5 in the end.
At this point the leading US Government candidate for winning the “warp speed” race to roll out a COVID-19 vaccine is Slaoui’s Moderna Inc. in Cambridge, Massachusetts. On April 16, Moderna got an award from US government agency BARDA for $483 million to accelerate development of mRNA-1273m, a gene-edited vaccine technology that is entirely experimental and has never before approved for use as a vaccine.
Dr. Slaoui also has ties to the projects of the Bill & Melinda Gates Foundation. He sat on the board of the Gates-funded International AIDS Vaccine Initiative. The IAVI was initiated in 1994 at a Rockefeller Foundation conference and is backed among others by the Gates Foundation, by the US Department of Defense and by Anthony Fauci’s National Institute of Allergy and Infectious Diseases.
Johnson & Johnson, which hopes to begin trials of its most promising potential vaccine at latest by the first week of September 2020, announced that it had struck a deal with the spook firm Emergent BioSolutions of Maryland to mass produce its product.
The U.S. Congress has directed almost $10 billion to this effort through supplemental funding, including the CARES Act, and Congress has appropriated other flexible funding. Over $6.5 billion has been designated by the US Congress for countermeasure development through the Biomedical Advanced Research and Development Authority (BARDA), along with $3 billion for NIH research.
The U.S. federal government is making investments in manufacturing and distribution at its own risk much earlier than usual, giving firms the knowledge that they can invest aggressively in the development.